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EXPERIENCES IN THE TREATMENT OF NEOPLASTIC
DISEASE WITH NITROGEN MUSTARD*
MAX TAFFEL
The reintroduction of poison gas in warfare by the Germans in
1915 stimulated experimental studies, both in the clinic and in the
animal laboratory, on the effect of these agents upon various body
structures. Between 1919 and 1921 several reports1' 5,6,78 appeared
describing the changes produced by mustard gas. The recent world
conflict stimulated further research relating to the properties of the
old gases and of new derivatives that might be used in combat. In the
course of these studies evidence was incidentally uncqvered which
suggested that one of the derivatives had potentialities for effective
therapeutic use in malignant disease. Owing to security restrictions
imposed by the war, the results of these latter studies were kept secret
until April 1946 when an article by Gilman and Philips2 appeared in
Science describing the biological actions and therapeutic applications
of the nitrogen mustards. Later that year two other reports3'4 were
published relating the accumulated experience of several investigators in
the use of this drug in 126 cases of neoplastic disease and allied dis-
orders of the hematopoietic system.
The purpose of this communication is to record the results obtained
in treating a group of similar diseases at the Tumor Clinic of the Yale
University School of Medicine. The series to be presented is admittedly
small. Its chief usefulness probably lies in the fact that it may be
added to other series and, by increasing the total number of observa-
tions, make possible a more accurate statistical analysis of the whole.
The trends observed in this small series compare favorably with those
noted by other investigators.
During the past three years 16 patientst with neoplastic disease
have been treated with a nitrogen mustard derivative, methyl-bis
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(,8-chloroethyl) amine hydrochloride. Ten were males and six were
females. The ages varied from six to seventy-two years. There were
six cases of Hodgkin's disease, two of stem-cell lymphoma, and one each
oflymphocytic lymphoma, lymphoblastic lymphoma, mycosis fungoides,
mycosisfungoideswith reticulum cell sarcoma,pleomorphiccell sarcoma
arising in giant follicle lymphoma, embryonal carcinoma of the testis,
fibrosarcoma of the chest wall, and Ewing tumor of the pelvic bone. In
each instance the diagnosis had been verified by biopsy before treat-
ment was instituted. Eleven of the patients had had previous x-ray
therapy for their disease; four had had no prior treatment; and in one
the primary tumor (testis) had been excised.
Dosageandmethod ofadministration
The course of treatment consisted, at first, of six consecutive, daily
intravenous administrations of the drug in doses of 0.1 mg. per kilo
of body weight. A fresh solution of the drug in saline was prepared
prior to each injection. More recently the course of treatment was cut
from six to four daily injections. Because of severe reactions, one
patient received only three doses, and another received 0.1 mg. per kilo
the first day and 0.05 mg. per kilo during each of the next four days.
In all, 20 courses of treatment were given, two patients with Hodgkin's
disease, one with lymphoblastic lymphoma, and one with lymphocytic
lymphoma receiving two separate courses each.
Sideeffectsofthedrug
Most of the patients experienced mild to moderate nausea and
vomiting during the course of treatment. No instance of bloody vomitus
was recorded. One patient suffered from severe nausea, vomiting, and
prostration, and received therefore only three doses. Another patient
became semi-comatose and died two days after treatment. It was in this
patient that the dose was cut down to 0.05 mg. per kilo per day. Al-
though at autopsy he showed evidence of marked arteriosclerotic heart
disease and congestive failure, it was felt that the drug had contributed
considerably to his demise.
In twelve instances there was no change in the red blood count.
In the remainingeightthere was adrop of about one million cells which
took place from the second day to the second week after the beginning
of treatment.
A sharp reduction in the number of lymphocytes was observed
eleven times (in 3 of these the count went down to 0); in five instances
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the reduction was moderate; and in four itwas negligible. The reduction
occurred within a day or two after the first injection and the maximum
drop was usually observed before the course of treatment had been
completed. The return to normal occurred in about two weeks.
Concomitant with the fall in lymphocytes there was often a relative
increase in the number of granulocytes. After two to three weeks a
definite granulocytopenia developed in 9 cases. This was severe (below
20 per cent) in 4 and moderate (20 to 45 per cent) in 5 others. In
10 instances there was no secondary granulocytopenia. One patient
died too soon after treatment for any change to occur. A severe
leukopenia (below 1000 cells per cubic millimeter of blood) occurred
five times and a moderate leukopenia (1000 to 2000 cells) 8 times.
A drop in the total white count to levels between 2000 and 4000 was
recorded five times. In one instance death occurred too soon for evalua-
tion, and in another there was no change in the count. The leukopenia
was usually observed at the same time that the granulocytopenia de-
veloped. Patients with severe leukopenia and granulocytopenia were
treated with frequent transfusions of blood and with penicillin. The
total white count and the granulocyte count returned to normal after
two to three weeks. During the period of agranulocytosis one patient
developed an abscess in apilonidal cyst, another had ulcerative tonsillitis
and aparonychia, and in a third there was an aggravation of an existing
infected scalp and osteomyelitis of the skull. All three patients recovered
from the infections.
An alarming thrombocytopenia developed six times. The drop in
the platelet count was observed from six days to four weeks after the
first injection. Four patients in this group exhibited moderate to severe
purpuric manifestations, one had a profuse menstrual flow, and one had
no demonstrable hemorrhagic changes. The thrombocytopenia was suc-
cessfully combated by frequent transfusions of blood.
Administration of the drug did not appear in any consistent manner
to initiate or to aggravate any abnormalities in blood chemistry. In all
the earlier cases determinations were made of total protein, albumin,
globulin, non-protein nitrogen, total and free cholesterol, amino acid
nitrogen, icterus index, and cephalin flocculation.
Results oftreatment
Hodgkin's disease (6 cases). In all 6 patients an appreciable
diminution in the size of the dispersed lesions was detected by x-ray
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and physical examination shortly after the administration of the drug.
Maximum regression occurred 10 to 14 days after treatment. Although
the regression was occasionally very dramatic, in no case was there a
complete, even if only temporary, disappearance of the disease. Four
patients in this group of six have already died, the survival period vary-
ing from five to twenty-four months after the onset of the disease, and
from two to eleven months after treatment with nitrogen mustard. The
periods of remission varied from less than two months to six months.
Two patients are still alive, 13 and 22 months, respectively, after the
onset of the disease. One of these, a woman of 34 years, has had two
courses of treatment with the drug. A remission period of only one and
one-halfmonths followed thefirstcourse. Because of severe involvement
of the cervical lymph nodes which threatened momentary respiratory
obstruction, the second course was combined with x-ray therapy. The
immediate responsewas onlymoderate, but not enough time has elapsed
for proper evaluation. In the second living patient, a girl of six, the
administration of the drug, at a time when the disease had become
resistant to x-ray treatment, was promptly followed by a pronounced
regression of all the involved nodes. Today, only three months after
treatment there are, however, signs of recurrence.
Lymphocytic lymphoma (1 case; 2 courses of nitrogen mustard
treatment). There was diminution in the size of the nodes, lasting only
three months. He was given a second course of treatment which resulted
in improvement lasting about six months. Because of rapidly increasing
bilateral pleural effusions which had necessitated frequent thoracenteses
he was given x-ray therapy in the hope of creating a synechia between
the visceral and parietal pleural layers. Temporary reduction in the
formation of pleural fluid was accomplished, but his course continued
progressively down-hill and he died 36 months after the onset of his
disease, 22 months after thefirst course of nitrogen mustard therapy, and
18 months after the second.
Lymphoblastic lymphoma (1 case; 2 courses of nitrogen mustard
treatment). No appreciable beneficial effect was produced by the first
course but subsequent x-ray therapy resulted in marked improvement
which lasted for about six months. A second course of drug treatment,
administered one month ago, has resulted thus far in a slight im-
provement. *
Stem-cell lymphoma (2 cases). In the first case no beneficial effect
was observed and the patient died 29 months after the onset of the
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disease and five months after the treatment. The second patient is
still alive 8 months after theonsetofthe disease. The drug, administered
4 months ago, has provided definite symptomatic improvement and the
patient, previously bedridden, is now able to get about and to resume
some of her household activities.
Mycosis fungoides (1 case). This colored woman of 22 years has
had diffuse lesions involving the skin of practically her entire body for
the past 7 years. Repeated biopsies have demonstrated a picture typical
of mycosis fungoides, but with no evidence of malignant change.
Multiple courses of x-ray therapy have succeeded in shrinking some of
the lesions and in alleviating only temporarily the severe itching of the
skin. A course of nitrogen mustard therapy, administered five months
ago, resulted in a very appreciable reduction in the size of all the skin
lesions and in a marked improvement, though not in a complete
cessation of the itching. These beneficial effects have lasted to date.
Mycosis fungoides with reticulum cell sarcoma (1 case). This
patient had a severe reaction from the drug and died two days after com-
pletion of the treatment. At autopsy he had diffuse neoplastic involve-
ment in addition to arteriosclerotic heart disease and signs of congestive
failure.
Pleomorphic cell sarcoma arising in giant follicle lymphoma (1
case). Roentgenograms taken twenty days after the initial injection of
the drug demonstrated an increase in the size of the chest lesions. The
patient died 6 years after the onset of the disease and one month after
drug treatment.
Embryonal carcinoma of the testis (1 case). An increase in the
size of the pulmonary metastases was noted on x-ray examination
twenty days after treatment with the drug. The patient was subsequently
given stilbestrol which seemed to hold the disease temporarily in check.
He died 13 months after the onset of his disease and 12 months after
nitrogen mustard therapy.
Fibrosarcoma of chest wall (1 case). This patient, a white male of
45 years, wascritically ill with a huge fibrosarcoma that had arisen from
the soft tissues of the left posterior chest wall. There were multiple
metastases in both lungs. Previous x-ray therapy at another hospital had
not been effective. In desperation a course of 4 daily injections of
nitrogen mustard was administered but no beneficial result was noted.
The patient died five months after the onset of the disease and three
weeks after the drug treatment.
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Ewing tumor of pelvic bone (1 case). A white lad, 18 years of age,
had been treated previously with x-radiation for a large tumor of the
pubic bone. Fairly prompt shrinking of the tumor occurred. A second
course of radiotherapy was given eight months later when he developed
pulmonary metastases. The metastases appeared to increase in size dur-
ingthe course of the radiation therapy and in desperation he was treated
with nitrogen mustard. This was followed by a definite symptomatic
improvement and by a slight diminution in the size of the pulmonary
metastases, as revealed by roentgen examination. The improvement has,
however, been only brief and at the present moment, less than two
months after treatment with the drug, he is already reporting a
recurrence of his former symptoms.
Conclusions
This series is too small to permit any proper statistical analysis.
Certain trends may, however, be noted:
(1) The drug was not curative in any of the cases in this group.
Ten patients have already died; six are still alive, but are far from
cured.
(2) Hodgkin's disease appeared to be most susceptible to the drug.
There was an early, often a marked, but always a relatively short-lived
reduction in the size of the lesions. With the possible exception of the
patient who had become resistant to the x-ray, the improvement was not
sufficient to delay death appreciably.
(3) One patient with mycosis fungoides received very substantial
benefit from the drug, thus far for a period of about five months; one
patient with stem-cell lymphoma is still symptomatically improved four
months after treatment; and onepatient with Ewing tumor of the pelvic
bone was improved for less than two months.
(4) The drug is not innocuous. It has a toxic, depressing effect upon
all the blood elements, and not infrequently brings about an alarming
degree of agranulocytic leukopenia and of thrombocytopenia.
In summary, it may be stated that the drug has a useful place in
the treatment of lymphomatous malignant disease and especially of
Hodgkin's disease. Its beneficial effects are similar in kind and often in
degree to those resulting from x-ray treatment. It has a particular field
of usefulness in patients who have become resistant to radiotherapy.
Its value in embryonal types of neoplastic disease outside of the
lymphoma group has as yet not been adequately studied. It is likely that
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it may cause temporary remissions, as it did in the one case of Ewing
tumor in this series, but it is doubtful if it will demonstrate any lasting
curative properties. In this Clinic, radiotherapy is still the treatment of
choice for any of the histological varieties of the lymphomata, provided
the disease is localized. The nitrogen mustard drug is reserved for those
patients who have diffuse systemic involvement and for those who have
become resistant to the x-ray.
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